Baker Bros. places a $250M bet on a potential rival to Regeneron and Novartis — with a $1B-plus payoff on the line
Kodiak Sciences disappointed plenty of investors when it priced its IPO shares $KOD at $10 a pop, well below the range, last fall. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
